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Abstracts / Urological Science 26 (2015) S36eS49 S41urinary symptoms such as frequency, urgency, and nocturia. Previous
study reported that patients with IC/BPS during the 3-year follow-up
period showed increased risk of bladder cancer than healthy controls.
However, a potential detection bias may exist when elevated risk for
bladder cancer within three years immediately following an IC/BPS diag-
nosis. There should be noted that it is also common for IC/BPS to coexist
with either unexplained medical conditions, such as ﬁbromyalgia, irritable
bowel syndrome, and chronic fatigue syndrome or confusable diseases
during diagnosis of IC/BPS, such as urolithiasis and urinary tract infection.
Therefore, we re-examined the risk of bladder cancer in a large population
based cohort of individuals with a new diagnosis of IC/BPS to assess a
potential detection bias.
Materials and methods: We performed a retrospective cohort study of
Longitudinal Health Insurance Database 2000 with newly diagnosis of IC/
BPS from 2002 through 2010. After limiting our sample to patients with IC/
BPS diagnosis (ICD-9 code 595.1 at least once during the study period), we
identiﬁed an IC/BPS cohort. We then excluded patients with diagnosis of
bladder cancer (ICD-9 codes, 180-189) before IC/BPS diagnosis. The pri-
mary outcome was the event of bladder cancer, determined by the record
with ICD-9 codes, 180-189 after the entry dates. We deﬁned the logit of
predicted probability of bladder cancer as a propensity score using the
following baseline characteristics: sex, age, date of diagnosis, comorbidity,
and smoking status. Subjects with IC/BPS were matched on a one-to one
basis with subjects with non-IC/BPS. We used chi-square tests to evaluate
associations between events of bladder cancer and patient-level covariates
(age, sex, comorbidity, smoking status). Next, we compared primary
outcome (events of bladder cancer) between IC/BPS and non-IC/BPS cohort
using multiple logistic regression. Analyses were performed using SPSS
version 22.
Results: After adjusted with propensity score-matching, we identiﬁed
1642 patients with diagnosis of IC/BPS and 1642 patients with non-IC/BPS
cohort. There is no statistically signiﬁcant association between comor-
bidity and bladder cancer except urolithiasis (P < 0.001) and urinary tract
infection (P ¼ 0.03). During the study period, 20 (1.2%) IC/BPS patients and
30 (1.8%) non-IC/BPS patients were diagnosed as having bladder cancer.
Chi-square test showed no difference of bladder cancer incidence between
IC/BPS and non-IC/BPS cohort (p ¼ 0.2). Moreover, the multiple logistic
regressions estimating the risk of bladder cancer showed no signiﬁcant
association among IC/BPS, sex, urolithiasis, and urinary tract infection
except age (B ¼ 0.02, p ¼ 0.005).
Conclusions: Our results imply us that IC/BPS is not related to bladder
cancer. The detection bias from previous study may be the results of either
an inadequate matching non-IC/BPS cohort or poor controlled confound-
ing factor.Moderated Poster-3Urolithiasis
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Purpose: To evaluate the efﬁcacy of ureteroscopic lithotripsy with pneu-
matic lithoclast and laser in management of upper ureteral stones.
Materials and methods: We retrospectively review the medical record.
Patients who underwent ureteroscopic lithotripsy by pneumatic lithoclast
and laser between January 2012 to January 2013 for upper ureteral stone in
Mackay Memorial Hospital were included. Cases with concurrent UTI and
acute renal failure were excluded. Invisible stones, loss follow-up or con-
current middle or lower ureteral stones were also excluded. Patient age,
method of lithotripsy, stone size and burden (based on KUB or CT), ureteralcatheter insertion and further ESWL or URSL for residual stone were
recorded.
Results: There were 216 patients identiﬁed. A total of 158 patients met
criteria (118 patients in pneumatic lithoclast group and 40 patients in laser
group). One hundred and seventy-eight ureteral stones (135 in pneumatic
lithoclast group and 43 in laser group respectively) were treated. Themean
age of pneumatic lithoclast and laser group was 53.5years (22-92 years)
and 52.9 years (21-69 years) respectively. The stone size and burden in
both groups were similar (p ¼ 0.44 and 0.45 respectively). There was a
mild trend of better stone free rate and lower secondary intervention rate
in laser group (p¼ 0.07 and p ¼ 0.09 respectively). No severe complication
(>Grade III Clavien classiﬁcation) were observed.
Conclusions: Use of laser lithotripsy in management of upper ureteral
stonewas associatedwith lower rate of ureteral catheter insertion.We also
observed a weak association of better stone free rate and lower secondary
intervention rate in laser lithotripsy group. They were both safe pro-
cedures without major complications.
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Purpose: To compare the efﬁcacy of prophylactic antibiotics in reduction
of post-surgical infections in patients undergoing extracorporeal shock
wave lithotripsy (ESWL).
Materials and methods: The study is a double-blind, prospective, ran-
domized placebo control trial. Between 2012 and 2014, patients with
preoperative sterile urine undergoing ESWL were randomly allocated by
the randomization ratio of 1:1 to receive prophylactic antibiotics with
single-dose oral levoﬂoxacin (500mg) or no treatment (control group),
respectively. Urine analysis and urine cultures were obtained between
postoperative day 5 and 7. Pyuria was deﬁned as S10 WBC/hpf. Signif-
icant bacteriuria was deﬁned as S105cfu uropathogens/ml. Febrile uri-
nary tract infection (fUTI) was deﬁned as body temperature of 38.0
Celsius degree with pyuria or signiﬁcant bacteriuria within 7 days post-
operatively.
Results: Initially, 274 patents underwent randomization with 139 and 135
patients in the control and levoﬂoxacin group, respectively. Finally, 206
patients (106 with placebo and 100 with levoﬂoxacin) with complete
followup of urine analysis were eligible for analysis. The rates of post-
operative pyuria were not signiﬁcantly different in patients with and
without prophylaxis (8% vs. 4.7% p ¼ 0.33). There was also no signiﬁcant
difference in rates of bacteriuria in patients with and without prophylaxis
(0% v.s. 1%, p¼ 0.49). Patients without followup of urine analysis and urine
culture were contacted with telephone and there was only patients with
post-operative fever in the levoﬂoxacin group (0% vs. 0.7%, p ¼ 0.49). As
preliminary results of the interim analysis revealed no beneﬁt of levo-
ﬂoxacin in preventing post-ESWL pyuria, bacteriuria and febrile urinary
tract infection, we terminated the study early before pre-planned sample
size is achieved.
Conclusion: The incidence of asymptomatic and febrile urinary tract
infection is low in patient underwent ESWL with pre-operative sterile
urine. Therefore, prophylactic antibiotics in these patients may be
unnecessary.
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